Two Sigma Advisers
KROS icon

Two Sigma Advisers’s Keros Therapeutics KROS Stock Holding History

Two Sigma Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-171,800
Closed -$3.5M – 1144
2025
Q4 		$3.5M Buy
171,800
+117,600
+217% +$2.06M 0.01% 967
2025
Q3 		$857K Buy
54,200
+37,100
+217% +$548K ﹤0.01% 1537
2025
Q2 		$228K Sell
17,100
-102,400
-86% -$1.38M ﹤0.01% 2070
2025
Q1 		$1.22M Buy
119,500
+98,800
+477% +$1.15M ﹤0.01% 1382
2024
Q4 		$328K Buy
20,700
+13,800
+200% +$717K ﹤0.01% 1946
2024
Q3 		$401K Sell
6,900
-10,900
-61% -$538K ﹤0.01% 1796
2024
Q2 		$813K Buy
17,800
+3,500
+24% +$188K ﹤0.01% 1658
2024
Q1 		$947K Buy
+14,300
New +$848K ﹤0.01% 1611
2021
Q4 		– Sell
-18,800
Closed -$744K – 2722
2021
Q3 		$744K Buy
18,800
+11,300
+151% +$402K ﹤0.01% 1751
2021
Q2 		$319K Buy
7,500
+3,000
+67% +$163K ﹤0.01% 2116
2021
Q1 		$277K Buy
+4,500
New +$285K ﹤0.01% 2250

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Two Sigma Advisers's KROS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 171,800 shares — an estimated $3.5M sold.

Two Sigma Advisers first reported a position in KROS in Q1 2021 and held it in 11 quarters. The position peaked at $3.5M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Two Sigma Advisers reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 171,800 Keros Therapeutics shares in Q1 2026, an estimated $3.5M.
  • Two Sigma Advisers first reported a position in Keros Therapeutics in Q1 2021 and held it in 11 quarters.
  • Two Sigma Advisers's Keros Therapeutics position peaked at $3.5M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.